VivoSeq
Hematology

Castleman Disease

14

Pipeline Programs↗

3

Active Trials↗

8

Companies Involved↗

Castleman disease is an emerging landscape with 14 programs across 8 companies. The most active players are RECORDATI GROUP, Boehringer Ingelheim, Avyxa. 5 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

0/100

Mech. Concentration

8/100

Completion Rate

33/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

RECORDATI GROUP

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2A

Avyxa

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2Roche logo

Roche

2 programs

Phase 2B

BeOne Medicines

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

71%

Small molecule

10 of 14 classified programs — the dominant modality here.

29%ALL OTHERSMonoclonal antibody429%

Small molecule leads; the ring shows all 14 classified programs, each share of the total. Modality classified for 100% of 14 pipeline programs.

Analysis

Trial Status

6

clinical trials

Terminated2 · 33%
Completed1 · 17%
Not yet recruiting1 · 17%
Active, not recruiting1 · 17%
Recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT06052618·75 enrolled
Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi
Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT04585893·15 enrolled
Nintedanib Treatment in Unicentric Castleman Disease
Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06643091·13 enrolled
Tocilizumab for KSHV-Associated Multicentric Castleman Disease
Completed·National Cancer Institute (NCI)·Phase 2·NCT01441063·8 enrolled
Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease
Terminated·RRECORDATI GROUP·Phase 2·NCT04838860·22 enrolled
Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy
Terminated·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00127569·25 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)